On Janaushadhi Diwas this year (i.e., March 7th, 2022), Prime Minister Shri Narendra Modi stated that the poor and the middle-class benefited from the 'Jan Aushadhi Kendras' that were set up to provide generic drugs at affordable prices. He said that the poor and the middle class saved around Rs.13,000 crore through these stores during the COVID-19 pandemic. In the wake of COVID 19 crisis, the 'Bureau of Pharma PSUs of India'...

-The Hindu The Health Ministry’s guidelines for managing COVID-19 ignore evidence, pricing, cost-effectiveness and social relevance. The Health Ministry released its first COVID-19 management guidelines about a year ago. The initial treatment guidelines included Hydroxychloroquine, which led to panic buying of the drug. Little was known in those initial months. In the last one year, multiple studies have proven the lack of efficacy of Hydroxychloroquine. While most practitioners have moved away from...

-The Times of India MUMBAI: Certain medicines are being aggressively marketed in India despite inadequate evidence of safety and efficacy, putting patients at risk, said reputed medical journal Lancet. Highlighting weak regulation and monitoring of the domestic drug industry, three recently-introduced medicines are being prescribed and sold though there is a lack of rigorous trials on crucial safety and efficacy parameters. The pharmaceutical industry in India should face the same stringent regulations...